• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Request Free Sample ×

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor
    Hero Background

    China Viscosupplementation Market

    ID: MRFR/HC/47666-HCR
    200 Pages
    Rahul Gotadki
    October 2025

    China Viscosupplementation Market Research Report By Type (Stabilized Hyaluronic Acid, Standard hyaluronic) and By Procedure (Three-Injection Procedure)- Forecast to 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    China Viscosupplementation Market Infographic

    China Viscosupplementation Market Summary

    The China Viscosupplementation market is projected to grow significantly from 195 USD Million in 2024 to 1426 USD Million by 2035.

    Key Market Trends & Highlights

    China Viscosupplementation Key Trends and Highlights

    • The market is expected to experience a compound annual growth rate (CAGR) of 19.83% from 2025 to 2035.
    • By 2035, the market value is anticipated to reach 1426 USD Million, indicating robust growth potential.
    • In 2024, the market is valued at 195 USD Million, laying a solid foundation for future expansion.
    • Growing adoption of viscosupplementation due to increasing prevalence of osteoarthritis is a major market driver.

    Market Size & Forecast

    2024 Market Size 195 (USD Million)
    2035 Market Size 1426 (USD Million)
    CAGR (2025-2035) 19.83%

    Major Players

    OrthogenRx, Bausch Health, Petros Pharmaceuticals, Fidia Farmaceutici, Revance Therapeutics, Baxter International, Hyaluronic Acid Company, DePuy Synthes, MediGus, Stryker Corporation, Galderma, Seikagaku Corporation, Anika Therapeutics, Zimmer Biomet, AptarGroup

    China Viscosupplementation Market Trends

    A major driving engine in the China Viscosupplementation market is the growing incidence of osteoarthritis among the senior population. The increasing number of older people has heightened the demand for efficient therapies for joint pain.

    Viscosupplementation is an attractive choice due to its potential to enhance joint function and reduce pain. Furthermore, increasing knowledge of the advantages of less invasive treatments helps explain the rise in its use.

    Among the possibilities to investigate are more manufacturer-healthcare provider alliances and broader distribution channel growth. Viscosupplementation goods might be more widely available if China's healthcare system keeps improving, especially in rural regions.

    The Chinese government's efforts to encourage health and well-being, especially in relation to senior care, also provide opportunities for development. Investments in research and development might result in creative formulations that improve treatment effectiveness and attract more customers.

    Recent trends indicate a growing demand for biological therapies as well as a move toward individualized medicine strategies. Patients are increasingly seeking customized solutions fit for their particular health requirements, hence opening a market for creative goods.

    Moreover, the digital change in healthcare, including telemedicine and online consultations, is changing how treatments are provided and how consumers interact with their health choices. For viscosupplementation businesses, the use of technology offers notable chances.

    This includes engaging directly with their target audience in patient education and marketing plans. The market is evolving with technological advancements and changing patient expectations.

     

    Market Segment Insights

    Viscosupplementation Market Type Insights

    The China Viscosupplementation Market is experiencing notable growth as the country increasingly focuses on advanced medical treatments for osteoarthritis and joint pain. The market is largely categorized by Type, with key segments including Stabilized Hyaluronic Acid and Standard Hyaluronic Acid.

    Stabilized Hyaluronic Acid holds a significant position due to its long-lasting effects and effectiveness in treating patients with severe joint issues. This type is prized for its ability to retain moisture, providing enhanced lubrication in joints.

    This is critical for improving mobility and reducing discomfort. In contrast, Standard Hyaluronic Acid also plays an important role but is primarily utilized in less severe cases and lower doses.

    Viscosupplementation Market Procedure Insights

    The Procedure segment of the China Viscosupplementation Market has garnered significant attention due to its role in managing osteoarthritis and joint-related issues. These issues are prevalent in the aging population of China.

    Among the various methods, the Three-Injection Procedure has become particularly noteworthy, as it typically offers enhanced long-term pain relief and improved mobility for patients. This approach involves a series of injections that deliver hyaluronic acid into the affected joints.

    This promotes lubrication and reduces inflammation. The growing awareness of non-surgical treatment options, driven by a rising emphasis on minimally invasive procedures, has positioned the Three-Injection Procedure as a preferred choice among both practitioners and patients.

    Get more detailed insights about China Viscosupplementation Market

    Key Players and Competitive Insights

    The China Viscosupplementation Market is characterized by a dynamic landscape that is significantly influenced by various factors such as advancements in technology, increasing consumer awareness, and changing demographics. As the healthcare system in China continues to evolve, the demand for effective joint pain management solutions has notably increased.

    This has led to a surge in the development and distribution of viscosupplementation products. The competitive environment includes a mix of both domestic and international players, each striving for market share through innovative products, effective marketing strategies, and strategic partnerships.

    As the market is driven by growing orthopedic procedures and an aging population, companies operating within this sphere need to navigate regulatory complexities and local preferences to successfully establish their presence in this lucrative market.

    OrthogenRx has made notable strides within the China Viscosupplementation Market, capitalizing on its strengths in product innovation and customer-centric approaches. The company has positioned itself strategically to cater to the unique needs of the Chinese market.

    This involves focusing on enhancing the efficacy of its viscosupplementation solutions. With a commitment to quality and patient outcomes, OrthogenRx has been able to penetrate healthcare facilities and network with key opinion leaders in orthopedics, thereby reinforcing its brand presence.

    The company’s ability to leverage localized marketing strategies and adapt global insights to the Chinese context has allowed it to forge strong relationships with healthcare professionals, making it a competitive player in this growing market.

    Bausch Health has also emerged as a significant competitor in the China Viscosupplementation Market, known for its robust portfolio of products aimed at enhancing joint health and mobility. The company’s key offerings in this arena include various viscosupplementation injections.

    These are designed to alleviate osteoarthritis symptoms. Bausch Health's strong market presence can be attributed to its commitment to research and development, resulting in innovative formulations that meet the demands of the Chinese healthcare landscape.

    Furthermore, the company's strategic mergers and acquisitions have expanded its capabilities and market reach, enabling it to deliver comprehensive solutions tailored to local patient needs. Bausch Health's focus on building partnerships with healthcare providers and institutions further solidifies its standing in the market.

    This showcases its strengths in navigating local regulations and capturing market opportunities effectively. Their approach emphasizes a deep understanding of the regional healthcare environment.

    Key Companies in the China Viscosupplementation Market market include

    Industry Developments

    Recent developments in the China Viscosupplementation Market have seen a significant focus on enhancing treatment options for osteoarthritis. Companies such as OrthogenRx, Bausch Health, and DePuy Synthes are actively participating in this sector.

    The market has witnessed growth in product innovations and formulations, aligning with increasing demand for effective joint therapies. In terms of mergers and acquisitions, there have been no publicly known activity reported for the specified companies in recent months within China.

    However, several industry players like Revance Therapeutics and Baxter International have been exploring strategic collaborations. The overall market valuation is on an upward trend, primarily driven by a rising geriatric population and the growing prevalence of joint disorders in China.

    These report substantial figures indicating unmet medical needs in this area. In the last few years, significant policy changes and regulatory approvals have facilitated market access for various viscosupplementation products, with a noted rise in consumer awareness.

    This awareness is regarding preventive and therapeutic measures against joint issues. As of September 2023, the market dynamics continue to evolve, with entities aiming to leverage local manufacturing capabilities to capture a larger share in the burgeoning demand for viscosupplementation therapies.

    Future Outlook

    China Viscosupplementation Market Future Outlook

    Market Segmentation

    Viscosupplementation Market Type Outlook

    • Stabilized Hyaluronic Acid
    • Standard hyaluronic

    Viscosupplementation Market Procedure Outlook

    • Three-Injection Procedure

    Report Scope

    Report Attribute/Metric Source:Details
    MARKET SIZE 2023177.53(USD Million)
    MARKET SIZE 2024195.0(USD Million)
    MARKET SIZE 20351426.0(USD Million)
    COMPOUND ANNUAL GROWTH RATE (CAGR)19.93% (2025 - 2035)
    REPORT COVERAGERevenue Forecast, Competitive Landscape, Growth Factors, and Trends
    BASE YEAR2024
    MARKET FORECAST PERIOD2025 - 2035
    HISTORICAL DATA2019 - 2024
    MARKET FORECAST UNITSUSD Million
    KEY COMPANIES PROFILEDOrthogenRx, Bausch Health, Petros Pharmaceuticals, Fidia Farmaceutici, Revance Therapeutics, Baxter International, Hyaluronic Acid Company, DePuy Synthes, MediGus, Stryker Corporation, Galderma, Seikagaku Corporation, Anika Therapeutics, Zimmer Biomet, AptarGroup
    SEGMENTS COVEREDType, Procedure
    KEY MARKET OPPORTUNITIESGrowing aging population, Rising osteoarthritis prevalence, Increased healthcare spending, Expanding awareness of treatments, Technological advancements in formulations
    KEY MARKET DYNAMICSrising osteoarthritis prevalence, increasing aging population, growing healthcare expenditure, advances in product formulations, favorable regulatory environment
    COUNTRIES COVEREDChina

    Leave a Comment

    FAQs

    What is the projected market size of the China Viscosupplementation Market in 2024?

    The China Viscosupplementation Market is expected to be valued at 195.0 million USD in 2024.

    What is the expected value of the China Viscosupplementation Market by 2035?

    The overall market is anticipated to reach 1426.0 million USD by the year 2035.

    What is the compound annual growth rate (CAGR) for the China Viscosupplementation Market from 2025 to 2035?

    The market is expected to grow at a CAGR of 19.827% during the period from 2025 to 2035.

    Which type of viscosupplement is expected to dominate the market by 2035?

    The Stabilized Hyaluronic Acid segment is projected to be valued at 640.0 million USD by 2035.

    How will the Standard Hyaluronic segment perform by 2035?

    The Standard Hyaluronic segment is expected to reach 786.0 million USD in valuation by the year 2035.

    What are some key players in the China Viscosupplementation Market?

    Major players include OrthogenRx, Bausch Health, Petros Pharmaceuticals, and Fidia Farmaceutici.

    What is the market size for the Stabilized Hyaluronic Acid segment in 2024?

    The Stabilized Hyaluronic Acid segment is valued at 85.0 million USD in 2024.

    What market opportunities exist for viscosupplementation in China?

    The market holds growth opportunities driven by increasing aging populations and joint health awareness.

    Is there any emerging trend influencing the China Viscosupplementation Market?

    There is a trend towards minimally invasive procedures, fueling demand for viscosupplementation therapies.

    What are the potential challenges for the market players in the China Viscosupplementation Market?

    Challenges include competitive pricing pressure and regulatory hurdles in the healthcare sector.

    Download Free Sample

    Kindly complete the form below to receive a free sample of this Report

    Case Study
    Chemicals and Materials

    Compare Licence

    ×
    Features License Type
    Single User Multiuser License Enterprise User
    Price $4,950 $5,950 $7,250
    Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
    Free Customization
    Direct Access to Analyst
    Deliverable Format
    Platform Access
    Discount on Next Purchase 10% 15% 15%
    Printable Versions